Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

EPX-HTG for Structural Heart Procedures (EPX-HTG-2026)

13 de julho de 2026 atualizado por: EchoPixel, Inc.

EchoPixel Holographic Therapy Guidance (HTG) for Structural Heart Procedures

To investigate and evaluate the benefits of adding EchoPixel Holographic Therapy Guidance to the current standard of care in Structural Heart (SH) procedures.

Current structural heart (SH) procedures rely on standard image guidance (SIG) relies on 2D X-plane or multiplanar reformatted (MPR) views that can conceal critical anatomy elements at the time of implant or therapy delivery which are crucial to achieve an optimal long term durable outcome.

This limitation complicates an operator's task of optimally implanting a 3D device, delivered by tools that rotate and maneuver in 3D, within a dynamic 3D anatomy, the heart. Slight mismatches between the device and the target in the heart are indicative of a sub-optimal device position, a key risk-factor of peri-device leak (PDL) and other complications.

The primary objective of the study is to determine if including EchoPixel - HTG as an additive visualization procedural tool has a positive impact on optimal procedure outcomes for patients undergoing in Structural Heart (SH) procedures.

Visão geral do estudo

Descrição detalhada

A prospective, single-center, clinical chart review.

In this trial, we will determine if the additional use of EchoPixel - HTG demonstrates a reduction in procedure time, decrease use of contrast and radiation, minimize the number of devices trialed during a procedure, determine ideal fluoroscopic viewing angles for device deployment, and optimize implant deployment and seal in in Structural Heart (SH) procedures.

The study team will compile the redacted pre- procedure CT, redacted procedural Trans-Esophageal Echo (TEE) or Intra-Cardiac Echo (ICE), procedural fluoroscopic imaging and the post device implant imaging created for each procedure case. Patient health information will be redacted and provided to physicians for review. Data will be collected on case report forms.

A prospective review will occur of outcomes regarding the Structural Heart (SH) procedure cases and data will be recorded on case report forms to compare to normal historical outcomes.

All available consecutive patients treated with the Watchman FLX device for Left Atrial Appendage Occlusion (LAAO) or MitraClip for Mitral Valve transcatheter edge to edge repair (M-TEER) will be reviewed. The primary endpoint will be to determine if EchoPixel - HTG assists in better guiding the implanter during the procedure.

All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE.

The Primary objective of the study is to determine if adding EchoPixel - HTG has a positive impact on optimal procedure success for patients undergoing an implantation of a Watchman FLX / MitraClip device compared to patients with current SIG. Procedural metrics and any procedural related complications will be recorded as secondary outcomes.

Patient demographics blinded procedural outcomes, pre-hospital discharge and complications will be monitored through and until the patient follow-up visit.

Study Execution.

Collection of data:

  1. All patients will be identified using a prospective review.
  2. The patients imaging will be de-identified and numbered with randomly picked research subject numbers identified only by site enrollment log (retained at the site only).
  3. All deidentified data imaging will be downloaded on the two separate BOX (part 11 FDA compliant) drives.

    1. CT data in one drive.
    2. TEE data in one drive.
    3. ICE data in one drive.
  4. All patient's demographics will be obtained (age, ethnicity, vitals, ejection fraction, EKG, hemoglobin, creatinine, medical history, concomitant medications, CHADS2-Vasc, HAS-BLED, primary reason for implant).

Analysis of procedural data:

  1. Procedure time in minutes.
  2. Fluoroscopic time in minutes.
  3. Radiation dose in mGy.
  4. Contrast used during the LAAO procedure in ml.
  5. Number of devices trialed during the LAAO / TEER procedure.
  6. Number of attempted device deployments / recaptures.
  7. Clinical outcomes and procedural related complications.
  8. Composite of procedure-related complications through follow-up visit.

Informed Consent Process. This is a prospective trial, utilizing redacted personal health information (PHI). Therefore, consent will be obtained.

Privacy, Confidentiality and Data Handling. The investigator will retain all regulatory documents pertaining to this study in compliance with ICH/GCP guidelines. This includes essential study documents and source documentation that support the data collected on the study Subjects. Each subject's study data will be collected and will be securely stored in the coordinating site's office. Subjects will be identified using a subject identification number. Subject information will be anonymized for data analysis.

RISKS to PARTICIPANTS. As a prospective study, all patients will be managed according to the practice's standard-of-care. As a result, there are no additional risks to the patients having their medical charts reviewed for this study. Staff and employees at the study site have extensive HIPAA training and all records will be retained at the institution. Data collection will involve the recording of protected health information; however, this PHI data will remain at the study site and only de-identified data will be shared with Echopixel. The Watchman FLX procedure / MitraClip is an FDA approved procedure.

BENEFITS to PARTICIPANTS. As an FDA approved device and procedure, there is no direct benefit to the patient. However, information gained from the study will contribute to the body of knowledge regarding the treatment of patients needing the LAAO/MitraClip procedure. Additionally, future patients who may want to consider a LAAO/MitraClip procedure will benefit from the collective published literature base of studies, such as this proposed study.

Tipo de estudo

Intervencional

Inscrição (Estimado)

20

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • California
      • Sacramento, California, Estados Unidos, 95187
        • University of California, Davis

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE.

Exclusion Criteria:

  • Patients whose procedures would require a GE or Siemens ultrasound system.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: EPX-HTG
Patients undergoing structural heart procedures (LAAO or M-TEER) including Holographic Therapy Guidance (HTG) as an additive visualization tool for procedure guidance.
Left Atrial Appendage Occlusion with HTG as an additive visualization tool for procedure guidance.
Outros nomes:
  • Vigia
Mitral Valve Transcatheter Edge to Edge Repair with HTG as an additive visualization tool for procedure guidance.
Outros nomes:
  • MitraClip
  • M-TEER

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Optimal Device Position.
Prazo: 45 days post procedure.
For both LAAO and M-TEER procedures an optimal device position will be established in pre-procedure planning. The optimal device position will be evaluated at the time of the procedure and in post-procedure imaging.
45 days post procedure.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Procedure Time.
Prazo: Perioperative/Periprocedural measurement of procedure length/duration.
Duration of procedure to implant LAAO or TEER device, in minutes.
Perioperative/Periprocedural measurement of procedure length/duration.
Fluoroscopic Time.
Prazo: Perioperative/Periprocedural measurement of length/duration of fluoroscopy use.
Duration/length of use of fluoroscopy to implant LAAO or TEER device, in minutes.
Perioperative/Periprocedural measurement of length/duration of fluoroscopy use.
Radiation Dose.
Prazo: Perioperative/Periprocedural measurement of total radiation dose for completing procedure/surgery.
Amount of radiation used to implant LAAO or TEER device in mGy.
Perioperative/Periprocedural measurement of total radiation dose for completing procedure/surgery.
Contrast Used.
Prazo: Perioperative/Periprocedural measurement of total radio-opaque contrast used for completing procedure/surgery.
Amount of radio-opaque contrast used to implant LAAO or TEER device, in ml.
Perioperative/Periprocedural measurement of total radio-opaque contrast used for completing procedure/surgery.
Number of devices trialed for procedure completion.
Prazo: Perioperative/Periprocedural count of the total number of devices (LAAO or TEER) utilized/required to complete the procedure/surgery.
The total number of devices (LAAO or TEER) utilized/required to complete the procedure.
Perioperative/Periprocedural count of the total number of devices (LAAO or TEER) utilized/required to complete the procedure/surgery.
Number of Device Deployments.
Prazo: Perioperative/Periprocedural count of the total number of times a device is positioned for final deployment in order to be released from the delivery catheter in order to complete the procedure/surgery/
The total number of times a device is positioned for final deployment in order to be released from the delivery catheter.
Perioperative/Periprocedural count of the total number of times a device is positioned for final deployment in order to be released from the delivery catheter in order to complete the procedure/surgery/
Procedure-related complications.
Prazo: Perioperative/Periprocedural and throughout 45-day follow-up visit.
Composite of any procedure-related complications for LAAO or M-TEER.
Perioperative/Periprocedural and throughout 45-day follow-up visit.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Gagan D Singh, MD, UC Davis Health

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

3 de agosto de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2026

Conclusão do estudo (Estimado)

30 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de julho de 2026

Primeira postagem (Real)

15 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

15 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever